IBDEI0YL ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,15620,1,4,0)
;;=4^E11.65
;;^UTILITY(U,$J,358.3,15620,2)
;;=^5002663
;;^UTILITY(U,$J,358.3,15621,0)
;;=E11.649^^61^760^21
;;^UTILITY(U,$J,358.3,15621,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15621,1,3,0)
;;=3^DM Type 2 Uncontrolled w/ Hypoglycemia w/o Coma
;;^UTILITY(U,$J,358.3,15621,1,4,0)
;;=4^E11.649
;;^UTILITY(U,$J,358.3,15621,2)
;;=^5002662
;;^UTILITY(U,$J,358.3,15622,0)
;;=I16.0^^61^760^44
;;^UTILITY(U,$J,358.3,15622,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15622,1,3,0)
;;=3^Hypertensive Urgency
;;^UTILITY(U,$J,358.3,15622,1,4,0)
;;=4^I16.0
;;^UTILITY(U,$J,358.3,15622,2)
;;=^8133013
;;^UTILITY(U,$J,358.3,15623,0)
;;=H54.8^^61^760^47
;;^UTILITY(U,$J,358.3,15623,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15623,1,3,0)
;;=3^Legal Blindness,USA Definition
;;^UTILITY(U,$J,358.3,15623,1,4,0)
;;=4^H54.8
;;^UTILITY(U,$J,358.3,15623,2)
;;=^5006369
;;^UTILITY(U,$J,358.3,15624,0)
;;=F10.10^^61^760^2
;;^UTILITY(U,$J,358.3,15624,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15624,1,3,0)
;;=3^Alcohol Abuse,Uncomplicated
;;^UTILITY(U,$J,358.3,15624,1,4,0)
;;=4^F10.10
;;^UTILITY(U,$J,358.3,15624,2)
;;=^5003068
;;^UTILITY(U,$J,358.3,15625,0)
;;=J30.9^^61^760^3
;;^UTILITY(U,$J,358.3,15625,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15625,1,3,0)
;;=3^Allergic Rhinitis,Unspec
;;^UTILITY(U,$J,358.3,15625,1,4,0)
;;=4^J30.9
;;^UTILITY(U,$J,358.3,15625,2)
;;=^5008205
;;^UTILITY(U,$J,358.3,15626,0)
;;=I48.0^^61^760^7
;;^UTILITY(U,$J,358.3,15626,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15626,1,3,0)
;;=3^Atrial Fibrillation Paroxysmal (PAF)
;;^UTILITY(U,$J,358.3,15626,1,4,0)
;;=4^I48.0
;;^UTILITY(U,$J,358.3,15626,2)
;;=^90473
;;^UTILITY(U,$J,358.3,15627,0)
;;=N18.1^^61^760^9
;;^UTILITY(U,$J,358.3,15627,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15627,1,3,0)
;;=3^CKD,Stage 1
;;^UTILITY(U,$J,358.3,15627,1,4,0)
;;=4^N18.1
;;^UTILITY(U,$J,358.3,15627,2)
;;=^5015602
;;^UTILITY(U,$J,358.3,15628,0)
;;=N18.2^^61^760^10
;;^UTILITY(U,$J,358.3,15628,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15628,1,3,0)
;;=3^CKD,Stage 2
;;^UTILITY(U,$J,358.3,15628,1,4,0)
;;=4^N18.2
;;^UTILITY(U,$J,358.3,15628,2)
;;=^5015603
;;^UTILITY(U,$J,358.3,15629,0)
;;=N18.4^^61^760^14
;;^UTILITY(U,$J,358.3,15629,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15629,1,3,0)
;;=3^CKD,Stage 4
;;^UTILITY(U,$J,358.3,15629,1,4,0)
;;=4^N18.4
;;^UTILITY(U,$J,358.3,15629,2)
;;=^5015605
;;^UTILITY(U,$J,358.3,15630,0)
;;=N18.5^^61^760^15
;;^UTILITY(U,$J,358.3,15630,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15630,1,3,0)
;;=3^CKD,Stage 5
;;^UTILITY(U,$J,358.3,15630,1,4,0)
;;=4^N18.5
;;^UTILITY(U,$J,358.3,15630,2)
;;=^5015606
;;^UTILITY(U,$J,358.3,15631,0)
;;=N18.6^^61^760^26
;;^UTILITY(U,$J,358.3,15631,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15631,1,3,0)
;;=3^ESRD
;;^UTILITY(U,$J,358.3,15631,1,4,0)
;;=4^N18.6
;;^UTILITY(U,$J,358.3,15631,2)
;;=^303986
;;^UTILITY(U,$J,358.3,15632,0)
;;=E11.22^^61^760^22
;;^UTILITY(U,$J,358.3,15632,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15632,1,3,0)
;;=3^DM Type 2 w/ CKD
;;^UTILITY(U,$J,358.3,15632,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,15632,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,15633,0)
;;=E11.319^^61^760^24
;;^UTILITY(U,$J,358.3,15633,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,15633,1,3,0)
;;=3^DM Type 2 w/ Retinopathy Unspec w/o Macular Edema
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0YL 3820 printed Nov 22, 2024@17:08:29 Page 2
IBDEI0YL ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,15620,1,4,0)
+2 ;;=4^E11.65
+3 ;;^UTILITY(U,$J,358.3,15620,2)
+4 ;;=^5002663
+5 ;;^UTILITY(U,$J,358.3,15621,0)
+6 ;;=E11.649^^61^760^21
+7 ;;^UTILITY(U,$J,358.3,15621,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,15621,1,3,0)
+10 ;;=3^DM Type 2 Uncontrolled w/ Hypoglycemia w/o Coma
+11 ;;^UTILITY(U,$J,358.3,15621,1,4,0)
+12 ;;=4^E11.649
+13 ;;^UTILITY(U,$J,358.3,15621,2)
+14 ;;=^5002662
+15 ;;^UTILITY(U,$J,358.3,15622,0)
+16 ;;=I16.0^^61^760^44
+17 ;;^UTILITY(U,$J,358.3,15622,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,15622,1,3,0)
+20 ;;=3^Hypertensive Urgency
+21 ;;^UTILITY(U,$J,358.3,15622,1,4,0)
+22 ;;=4^I16.0
+23 ;;^UTILITY(U,$J,358.3,15622,2)
+24 ;;=^8133013
+25 ;;^UTILITY(U,$J,358.3,15623,0)
+26 ;;=H54.8^^61^760^47
+27 ;;^UTILITY(U,$J,358.3,15623,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,15623,1,3,0)
+30 ;;=3^Legal Blindness,USA Definition
+31 ;;^UTILITY(U,$J,358.3,15623,1,4,0)
+32 ;;=4^H54.8
+33 ;;^UTILITY(U,$J,358.3,15623,2)
+34 ;;=^5006369
+35 ;;^UTILITY(U,$J,358.3,15624,0)
+36 ;;=F10.10^^61^760^2
+37 ;;^UTILITY(U,$J,358.3,15624,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,15624,1,3,0)
+40 ;;=3^Alcohol Abuse,Uncomplicated
+41 ;;^UTILITY(U,$J,358.3,15624,1,4,0)
+42 ;;=4^F10.10
+43 ;;^UTILITY(U,$J,358.3,15624,2)
+44 ;;=^5003068
+45 ;;^UTILITY(U,$J,358.3,15625,0)
+46 ;;=J30.9^^61^760^3
+47 ;;^UTILITY(U,$J,358.3,15625,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,15625,1,3,0)
+50 ;;=3^Allergic Rhinitis,Unspec
+51 ;;^UTILITY(U,$J,358.3,15625,1,4,0)
+52 ;;=4^J30.9
+53 ;;^UTILITY(U,$J,358.3,15625,2)
+54 ;;=^5008205
+55 ;;^UTILITY(U,$J,358.3,15626,0)
+56 ;;=I48.0^^61^760^7
+57 ;;^UTILITY(U,$J,358.3,15626,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,15626,1,3,0)
+60 ;;=3^Atrial Fibrillation Paroxysmal (PAF)
+61 ;;^UTILITY(U,$J,358.3,15626,1,4,0)
+62 ;;=4^I48.0
+63 ;;^UTILITY(U,$J,358.3,15626,2)
+64 ;;=^90473
+65 ;;^UTILITY(U,$J,358.3,15627,0)
+66 ;;=N18.1^^61^760^9
+67 ;;^UTILITY(U,$J,358.3,15627,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,15627,1,3,0)
+70 ;;=3^CKD,Stage 1
+71 ;;^UTILITY(U,$J,358.3,15627,1,4,0)
+72 ;;=4^N18.1
+73 ;;^UTILITY(U,$J,358.3,15627,2)
+74 ;;=^5015602
+75 ;;^UTILITY(U,$J,358.3,15628,0)
+76 ;;=N18.2^^61^760^10
+77 ;;^UTILITY(U,$J,358.3,15628,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,15628,1,3,0)
+80 ;;=3^CKD,Stage 2
+81 ;;^UTILITY(U,$J,358.3,15628,1,4,0)
+82 ;;=4^N18.2
+83 ;;^UTILITY(U,$J,358.3,15628,2)
+84 ;;=^5015603
+85 ;;^UTILITY(U,$J,358.3,15629,0)
+86 ;;=N18.4^^61^760^14
+87 ;;^UTILITY(U,$J,358.3,15629,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,15629,1,3,0)
+90 ;;=3^CKD,Stage 4
+91 ;;^UTILITY(U,$J,358.3,15629,1,4,0)
+92 ;;=4^N18.4
+93 ;;^UTILITY(U,$J,358.3,15629,2)
+94 ;;=^5015605
+95 ;;^UTILITY(U,$J,358.3,15630,0)
+96 ;;=N18.5^^61^760^15
+97 ;;^UTILITY(U,$J,358.3,15630,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,15630,1,3,0)
+100 ;;=3^CKD,Stage 5
+101 ;;^UTILITY(U,$J,358.3,15630,1,4,0)
+102 ;;=4^N18.5
+103 ;;^UTILITY(U,$J,358.3,15630,2)
+104 ;;=^5015606
+105 ;;^UTILITY(U,$J,358.3,15631,0)
+106 ;;=N18.6^^61^760^26
+107 ;;^UTILITY(U,$J,358.3,15631,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,15631,1,3,0)
+110 ;;=3^ESRD
+111 ;;^UTILITY(U,$J,358.3,15631,1,4,0)
+112 ;;=4^N18.6
+113 ;;^UTILITY(U,$J,358.3,15631,2)
+114 ;;=^303986
+115 ;;^UTILITY(U,$J,358.3,15632,0)
+116 ;;=E11.22^^61^760^22
+117 ;;^UTILITY(U,$J,358.3,15632,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,15632,1,3,0)
+120 ;;=3^DM Type 2 w/ CKD
+121 ;;^UTILITY(U,$J,358.3,15632,1,4,0)
+122 ;;=4^E11.22
+123 ;;^UTILITY(U,$J,358.3,15632,2)
+124 ;;=^5002630
+125 ;;^UTILITY(U,$J,358.3,15633,0)
+126 ;;=E11.319^^61^760^24
+127 ;;^UTILITY(U,$J,358.3,15633,1,0)
+128 ;;=^358.31IA^4^2
+129 ;;^UTILITY(U,$J,358.3,15633,1,3,0)
+130 ;;=3^DM Type 2 w/ Retinopathy Unspec w/o Macular Edema
